Medaphor Group PLC Completion of Acquisition (8775S)
06 October 2017 - 6:00PM
UK Regulatory
TIDMMED
RNS Number : 8775S
Medaphor Group PLC
06 October 2017
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Completion of Acquisition
Total Voting Rights
Director/PDMR Shareholding
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces that following admission
today of 56,477,285 new ordinary shares of 1 pence each ("Ordinary
Shares") relating to the placing to raise approximately GBP5.5
million and the Company's proposed acquisition of Intelligent
Ultrasound Limited for a total consideration of up to GBP3.6
million, both the placing and the acquisition have completed.
Following admission, the share capital of the Company will
consist of 90,701,443 Ordinary Shares. Therefore, the total number
of voting rights in the Company is 90,701,443 and this figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company.
The Company makes the following disclosures in respect of the
participation in the Placing by persons discharging managerial
responsibilities and persons closely associated, in accordance with
article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial
responsibilities / person closely associated
---- ------------------------------------------------------------------------
a) Name IP Group plc
---- --------------------------- -------------------------------------------
2 Reason for the notification
---- ------------------------------------------------------------------------
a) Position/status Person closely associated - David
Baynes, Non-Executive Director
---- --------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
---- --------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ------------------------------------------------------------------------
a) Name MedaPhor Group plc
---- --------------------------- -------------------------------------------
b) LEI N/A
---- --------------------------- -------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ------------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each
the financial
instrument, type
of instrument
----
Identification ISIN: GB00BN791Q39
code
---- --------------------------- -------------------------------------------
b) Nature of the Purchase of ordinary shares of
transaction 1 pence each as part of a placing
Consideration payable in ordinary
shares of 1 pence each as part
of an acquisition
---- --------------------------- -------------------------------------------
c) Price(s) and volume(s)
---- --------------------- -----------------
Price(s) Volume(s)
---- --------------------- -----------------
12.50 pence 16,000,000
------------------------------------------------------ -----------------
16.22 pence 5,055,320
------------------------------------------------------ -----------------
d) Aggregated information
----
- Aggregated volume 16,000,000 (being the placing
shares)
- Price GBP2,000,000
- Aggregate volume 5,055,320 (being the consideration
shares)
- Price
GBP819,972.90
--------------------------- ------------------------------------------------
e) Date of the transaction 6 October 2017
---- --------------------------- -------------------------------------------
f) Place of the transaction XLON
---- --------------------------- -------------------------------------------
Enquiries:
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075
6534
Cenkos Securities Tel: +44 (0)20 7397
8900
Bobbie Hilliam (Nominated
Advisor)
Michael Johnson / Julian
Morse (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob:
Dunphy +44 (0)7876 741 001
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops advanced hi-fidelity haptic and
manikin based training simulators, clinical image analysis software
tools, augmented reality based needle guidance software and
artificial intelligence based automated scanning software for all
medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US,
MedaPhor is split into two divisions:
Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through
simulation. Its three main products are the ScanTrainer OBGYN and
General Medical simulator training platform, the HeartWorks
echocardiography simulator platform and the BodyWorks Point-of-Care
simulator platform (launching January 2018). Over 500 MedaPhor
simulators have been sold to over 300 medical institutions in over
30 countries around the world.
Intelligent Ultrasound
Focuses on developing augmented reality and deep-learning based
algorithms to make ultrasound machines smarter and more accessible.
ScanNav uses machine-learning based algorithms to automatically
access and grade ultrasound images to provide scan assessment and
audit of obstetric scanning. NeedleGuide aims to simplify
ultrasound-guided needling by using deep learning and augmented
reality to provide the user with pathway guidance and automated
tracking for a range of medical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFSUFWIFWSEIS
(END) Dow Jones Newswires
October 06, 2017 03:00 ET (07:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024